Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.46 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 4/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389011 | 0.95 | GSK3B (0.50) | GSK3BNFATC1DYRK1ACNR2TGFBR1 | |
| SCHEMBL3391836 | 0.87 | GSK3B (0.48) | GSK3BNFATC1DYRK1ACNR2CDK1 | |
| SCHEMBL3384191 | 0.79 | IDO1 (0.42) | TGFBR1CYP1A2CYP3A4 | |
| SCHEMBL245858 | 0.78 | IDO1 (0.39) | GSK3BTGFBR1CYP1A2CYP3A4ACVR1B | |
| SCHEMBL3389923 | 0.77 | GSK3B (0.40) | GSK3BTGFBR1CYP1A2CYP3A4ACVR1B | |
| Formic Acid SCHEMBL248032 | 0.75 | TGFBR1 (0.47) | GSK3BNFATC1DYRK1ATGFBR1CYP1A2 | |
| SCHEMBL3381872 | 0.75 | HTR1A (0.38) | TGFBR1CYP1A2CYP3A4ACVR1BACVRL1 | |
| SCHEMBL3385992 | 0.74 | HTR6 (0.39) | TGFBR1CYP1A2CYP3A4ACVR1BPIM1 | |
| SCHEMBL3380840 | 0.74 | IDO1 (0.37) | TGFBR1CYP1A2CYP3A4ACVR1BACVRL1 | |
| SCHEMBL12440044 | 0.74 | FEN1 (0.43) | TGFBR1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2585461-A1 | 2,4- DIARYL - SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | Merck Patent GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | GSK3B 164/4885NFATC1 860/4885DYRK1A 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.